Christopher Degnan
2021
In 2021, Christopher Degnan earned a total compensation of $1.3M as Chief Financial Officer at Galera Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $121,917 |
|---|---|
| Option Awards | $744,195 |
| Salary | $395,833 |
| Other | $11,600 |
| Total | $1,273,545 |
Degnan received $744.2K in option awards, accounting for 58% of the total pay in 2021.
Degnan also received $121.9K in non-equity incentive plan, $395.8K in salary and $11.6K in other compensation.
Rankings
In 2021, Christopher Degnan's compensation ranked 7,897th out of 12,415 executives tracked by ExecPay. In other words, Degnan earned more than 36.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,897 out of 12,415 | 36th |
Division Manufacturing | 3,493 out of 5,508 | 37th |
Major group Chemicals And Allied Products | 1,557 out of 2,378 | 35th |
Industry group Drugs | 1,384 out of 2,099 | 34th |
Industry Pharmaceutical Preparations | 1,025 out of 1,549 | 34th |
Source: SEC filing on April 28, 2022.
Degnan's colleagues
We found two more compensation records of executives who worked with Christopher Degnan at Galera Therapeutics in 2021.
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020